Kezar Life Sciences, Inc.

Equities

KZR

US49372L1008

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.8049 ^USD	+1.89%		+1.89%	-15.04%

Mar. 14	Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 14	Kezar Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 14, 2024 at 04:16 pm EDT

Kezar Life Sciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 101.87 million compared to USD 68.24 million a year ago. Basic loss per share from continuing operations was USD 1.4 compared to USD 1.01 a year ago.

Latest news about Kezar Life Sciences, Inc.

Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Kezar Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
Kezar Life Sciences, Inc.(NasdaqGS:KZR) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Wells Fargo Adjusts Price Target on Kezar Life Sciences to $2 From $4, Maintains Equal-Weight Rating	Nov. 14	MT
Kezar Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
North American Morning Briefing : Investors Await -2-	23-10-06	DJ
JonesTrading Downgrades Kezar Life Sciences to Hold From Buy	23-10-05	MT
Kezar Life Sciences Launches Restructuring Program, Cuts Workforce, Names New CEO	23-10-03	MT
Kezar Life Sciences, Inc. Announces Executive Changes	23-10-03	CI
Kezar Life Sciences, Inc. Announces CEO Changes	23-10-03	CI
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway	23-10-03	CI
HC Wainwright Raises Kezar Life Sciences Price Target to $20 From $18, Maintains Buy Rating	23-09-25	MT
Sector Update: Health Care Stocks Tick Lower Thursday Morning	23-09-21	MT
North American Morning Briefing : The Post-Fed Selloff Continues	23-09-21	DJ
Kezar Life Sciences Signs License Agreement With Everest Medicines to Develop, Market Zetomipzomib in Asia	23-09-21	MT
Everest Medicines Signs License Deal with Kezar for Anti-Autoimmune Disease Medication	23-09-20	MT
Stocks to Watch : FedEx, Kezar Life Sciences, Transcat	23-09-20	DJ
Everest Medicines Enters into Collaboration and License Agreement with Kear Life Sciences to Develop and Commercialize Zetomipzomib in Greater China and Other Asian Markets	23-09-20	CI
Transcript : Kezar Life Sciences, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 10:50 AM	23-09-12
North American Morning Briefing : Stock Futures -2-	23-08-14	DJ
Wells Fargo Downgrades Kezar Life Sciences to Equalweight From Overweight	23-08-11	MT
HC Wainwright Adjusts Price Target on Kezar Life Sciences to $18 From $19, Maintains Buy Rating	23-08-11	MT
Kezar Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Kezar Life Sciences, Inc.(NasdaqGS:KZR) dropped from S&P Biotechnology Select Industry Index	23-06-20	CI
HC Wainwright Adjusts Price Target on Kezar Life Sciences to $19 From $21, Keeps Buy Rating	23-05-12	MT

Chart Kezar Life Sciences, Inc.

Duration

Period

More charts

Company Profile

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Kezar Life Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.8049 USD

Average target price

11.67 USD

Spread / Average Target

+1,349.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KEZAR LIFE SCIENCES, INC.	-15.04%	58.6M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs